Cover Image
市場調查報告書

美國的乾癬生技藥品、生物相似藥治療藥市場

The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis

出版商 MP Advisors 商品編碼 565345
出版日期 內容資訊 英文 104 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的乾癬生技藥品、生物相似藥治療藥市場 The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis
出版日期: 2017年10月13日 內容資訊: 英文 104 Pages
簡介

本報告以美國的乾癬治療用的生技藥品、生物相似藥市場為研究主題,提供生技藥品治療藥的主要上市產品,開發中產品,影響成長要素,及競爭情形,生物相似藥的已經過核准產品,臨床實驗中的產品,影響成長要素,及競爭情形等相關分析。

第1章 乾癬市場概要

第2章 乾癬的生技藥品治療藥市場

  • 簡介、市場概要
  • 美國的生技藥品的收益分析
  • 乾癬治療藥的主要上市產品
    • Remicade (infliximab; Janssen)
    • Humira (adalimumab; AbbVie)
    • Stelara (ustekinumab; Janssen)
    • Cosentyx (secukinumab; Novartis)
    • Taltz (ixekizumab; Lilly)
    • Siliq (brodalumab; Valeant)
    • Tremfya (guselkumab; Janssen)
  • 乾癬治療藥主要的開發中產品
    • Tildrakizumab; Merck / Sun Pharma
    • Cimzia (certolizumab pegol; UCB/Dermira Pharmaceuticals)
    • Risankizumab; AbbVie/Boehringer Ingelheim
  • 生技藥品的促進成長要素、抑制因素
  • 競爭情形:認證產品
  • 競爭情形:開發中產品

第3章 乾癬的生物相似藥市場

  • 簡介、市場概要
  • 已經過核准生物相似藥
    • 美國的已經過核准生物相似藥
    • 美國的生物相似藥的收益分析
    • EU的已經過核准生物相似藥
  • 開發平台分析
    • 臨床實驗:Humira (adalimumab)的生物相似藥
    • 臨床實驗:Enbrel (etanercept)的生物相似藥
    • 臨床實驗:Remicade (infliximab)的生物相似藥
  • 生物相似藥契約、聯盟
  • 生物相似藥的促進成長要素、抑制因素
  • 競爭情形:美國、EU的已經過核准生物相似藥
  • 競爭情形:TNFAlpha阻礙生物相似藥的開發平台

參考資料

目錄
Product Code: 4496

The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation biologics.

The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents. The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents.

Driven by improved efficacy, the first group of anti TNF treatments led by Enbrel, Humira and Remicade made strong penetration into the psoriasis market. However the emergence of the IL-17 inhibitor class driven by Novartis' Cosentyx and Eli Lilly's Talz have set a new benchmark for efficacy in moderate to severe psoriasis treatment with potential for safety improvement in comparison to the anti TNF drugs given their greater specificity in immune Suppression. MP Advisors expect the TNF class of drugs to lose share to the newer brands with improved clinical profiles in Psoriasis.

The market growth in psoriasis is driven by an upsurge in demand from new therapies in moderate to severe patient population which overshadows reduced pricing of branded TNF-α inhibitor and recent biosimilar launches. The psoriasis treatment market is facing increasing competitive pressure from a wave of biosimilar launches such as biosimilars of Janssen's Remicade, and Amgen's Enbrel with the impact of the headwinds expected to be more pronounced in the next few years.

Stelara has been an important growth driver of Janssen's immunology franchise in recent years, with overall global sales doubling from $1.5bn in 2013 to more than $3.2bn in 2016. However Stelara has started to face steeper competition from the IL-17 drug class. A new head-to-head study report IL-17 products to demonstrate superior efficacy to Stelara for psoriasis.

Table of Contents

Executive Summary

List of Figures

List of Tables

1. Psoriasis Market Overview

  • 1.1. Disease background
  • 1.2. Types of psoriasis
    • 1.2.1. Plaque psoriasis
    • 1.2.2. Guttate psoriasis
    • 1.2.3. Inverse (flexural) psoriasis
    • 1.2.4. Pustular psoriasis
    • 1.2.5. Erythrodermic psoriasis
  • 1.3. Pathophysiology
  • 1.4. Etiology
    • 1.4.1. Environmental factors
    • 1.4.2. Genetic factors
    • 1.4.3. Immunologic factors
  • 1.5. Risk factors and co-morbidities
  • 1.6. Epidemiology
  • 1.7. Treatment options
    • 1.7.1. Phototherapy
    • 1.7.2. Topical treatments
    • 1.7.3. Conventional systemic agents
    • 1.7.4. Other systemic drugs
    • 1.7.5. Biologics
  • 1.8. Treatment Guidelines
    • 1.8.1. Mild to moderate Psoriasis
    • 1.8.2. Moderate Psoriasis
    • 1.8.3. Moderate -to-severe psoriasis
    • 1.8.4. Severe psoriasis

2. Psoriasis Treatment Market for Biologics

  • 2.1. Introduction and Market Overview
  • 2.2. Revenue Analysis for Biologics in the U.S.
  • 2.3. Key marketed products for psoriasis treatment
    • 2.3.1. Remicade (infliximab; Janssen)
    • 2.3.2. Humira (adalimumab; AbbVie)
    • 2.3.3. Stelara (ustekinumab; Janssen)
    • 2.3.4. Cosentyx (secukinumab; Novartis)
    • 2.3.5. Taltz (ixekizumab; Lilly)
    • 2.3.6. Siliq (brodalumab; Valeant)
    • 2.3.7. Tremfya (guselkumab; Janssen)
  • 2.4. Key pipeline products for psoriasis treatment
    • 2.4.1. Tildrakizumab; Merck / Sun Pharma
    • 2.4.2. Cimzia (certolizumab pegol; UCB/Dermira Pharmaceuticals)
    • 2.4.3. Risankizumab; AbbVie/Boehringer Ingelheim
  • 2.5. Growth Drivers and Resistors for Biologics
    • 2.5.1. Growth Drivers:
    • 2.5.2. Resistors
  • 2.6. Competitive Landscape - Approved Products
  • 2.7. Competitive Landscape - Pipeline Products

3. Psoriasis Market for Biosimilars

  • 3.1. Introduction and Market Overview
  • 3.2. Approved biosimilars
    • 3.2.1. Approved biosimilars in the U.S.
    • 3.2.2. Revenue Analysis for Biosimilars in U.S.
    • 3.2.3. Approved biosimilars in the EU
  • 3.3. Pipeline Analysis
    • 3.3.1. Clinical development - Humira (adalimumab) biosimilars
    • 3.3.2. Clinical development - Enbrel (etanercept) biosimilars
    • 3.3.3. Clinical development - Remicade (infliximab) biosimilars
  • 3.4. Biosimilars deals and partnerships
  • 3.5. Growth Drivers and Resistors for Biosimilars
    • 3.5.1. Growth Drivers
    • 3.5.2. Resistors
  • 3.6. Competitive Landscape - Approved Biosimilars in the U.S. and EU
  • 3.7. Competitive Landscape - TNF α Inhibitors Biosimilars Pipeline

References:

Back to Top